Buffer

PreclinicalSmall molecule

NNorthwestern University

Buffer is one of 4 small molecule programs targeting Pain Perception. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pain PerceptionActive, not recruiting

Pain PerceptionPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Pain Perception

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

2 2

Tylenol

KKenvue Brands

Approved

1 3

Yohimbine

NNational Institute of Mental Health (NIMH)

Preclinical

1 4

Buffer

NNorthwestern University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infertility1 trial

A Study of Lidocaine Pertubation as a Treatment for Unexplained Infertility

Unknown status·IIsifer AB·Phase 2·NCT03386552·120 enrolled

Pain Perception1 trial

Pain Perception: Lidocaine Rate/Temp/Buffer

Active, not recruiting·NNorthwestern University·N/A·NCT02823002·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Buffer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buffer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buffer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthwestern University

Buffer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infertility1 trial

Pain Perception1 trial

References

Drug Info

Quick Facts

Related News